IRLAB Therapeutics: USD4m payment from MSRD to advance IRL757 - Redeye

Redeye provides a short comment on IRLAB’s announcement that MSRD (Otsuka) has issued a USD4m payment to advance IRL757 into a phase Ib study in Parkinson’s patients with apathy. With regulatory preparations now completed and first patient enrollment expected before year-end, the program remains on track.

Länk till analysen i sin helhet: https://www.redeye.se/research/1129334/irlab-therapeutics-usd4m-payment-from-msrd-to-advance-irl757?utm_source=finwire&utm_medium=RSS